Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. News
  7. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/25 11:35:05 am
6.45 GBX   -3.73%
04:44aSAREUM : Final Results
PU
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sareum : Patent Notice of Allowance for SDC-1802

07/30/2021 | 04:49am EDT

SAREUM HOLDINGS PLC

('Sareum' or 'the Company')

US Patent Notice of Allowance for Sareum's SDC-1802

Cambridge, UK, 30 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the 'SDC-1802 Programme').

The patent (US Patent Application no. 16/343,639) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.

The Company expects that the patent will be granted within three months, subject to certain formalities being completed.

Sareum's CSO, Dr John Reader, commented:

'The granting of this patent in the US will provide a further layer of protection around SDC-1802 following the granting of patents protecting the molecule in the US and other major markets in recent years. These patents are important to enhancing the value of the programme as part of our discussions with potential partners.'

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

020 3764 2341

MEDiSTRAVA Consulting (Financial PR)

Mark Swallow / David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

Disclaimer

Sareum Holdings plc published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 08:48:07 UTC.


ę Publicnow 2021
All news about SAREUM HOLDINGS PLC
04:44aSAREUM : Final Results
PU
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
07/19FTSE 100 Closes Down as Covid Cases Rise
DJ
07/19ALAN JOPE : FTSE 100 Slides as Virus Jitters Weigh
DJ
07/19SAREUM : Subscription to raise ú1,000,000
PU
More news
Financials
Sales 2021 0,17 M 0,23 M 0,23 M
Net income 2021 -1,63 M -2,24 M -2,24 M
Net Debt 2021 - - -
P/E ratio 2021 -134x
Yield 2021 -
Capitalization 217 M 299 M 299 M
Capi. / Sales 2021 1 277x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,6%
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,07 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC176.29%310
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610